Systemic and organ-specific immune-related manifestations of COVID-19

COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a case series from a tertiary care pediatric hospital in Qatar

“…This is in contrast to the findings of a study which showed a positive correlation between IL-6 level and fibrinogen level in patients with COVID-19 associated ARDS [22]. Other studies suggest that the cytokine storm in MIS-C patients differs from those in severe acute COVID-19 and hypothesize the role of autoantibodies such as lupus anticoagulants in COVID-19 associated coagulopathy and thrombosis [23][24][25].…”

Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection

“…The pathophysiologic mechanisms underlying post-acute COVID-19 syndrome are likely to be multifactorial in such patients, and physical deconditioning [ 30 ], psychologic disorders [ 31 ], viral encephalitis [ 7 ], dysautonomia [ 32 ] and autoimmunity are plausible suspects which could co-exist. Indeed, autoimmunity has been documented following COVID-19 [ 10 , 33 ]. However, viral-induced autoimmunity is likely transient, as demonstrated by the negative repeat screening for antiphospholipid antibodies in eight initially positive patients.…”

“…However, these pathologic mechanisms are less likely to explain the manifestations in patients with initially non-severe COVID-19 who go on to experience long-lasting symptoms. Among those plausible mechanisms, viral-induced autoimmunity should be investigated in light of the accumulating data reporting this phenomenon during or following acute COVID-19 [ 10 ]. Although 10% of COVID-19 patients may show chronic symptoms (> 12 weeks) [ 11 ], data on the clinical presentation, biologic characteristics and overall prognosis of such patients are scarce [ 9 , 12 ].…”

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

“…, поразила более 150 млн человек во всех регионах земного шара и привела более чем к 3 млн летальных исходов [2]. За время, прошедшее с начала пандемии, было проведено беспрецедентное число клинических и экспериментальных исследований, привлекших пристальное внимание к ревматологическим проблемам COVID-19, что в свою очередь во многом способствовало совершенствованию подходов к ведению пациентов [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17].…”

“…Инфекция SARS-CoV-2 сопровождается развитием системных клинических и лабораторных нарушений, некоторые из которых характерны для иммуновоспалительных ревматических заболеваний (ИВРЗ) и других аутоиммунных и аутовоспалительных болезней человека [16,29,30,31]. К ним относятся лихорадка, депрессивные и тревожные расстройства, фибромиалгия, хроническая усталость, артралгии, артрит, миалгии, миопатия, аутоиммунные цитопении, васкулопатия, поражение центральной и периферической нервной системы, кожи, экзокринных желез, патология легких, а аутоиммунный компонент представлен в первую очередь гиперпродукцией антифосфолипидных и антиядерных аутоантител.…”